Gray zone in the spectrum of autoinflammatory diseases: familial Mediterranean fever accompanying periodic fever, aphthous stomatitis, pharyngitis, and adenitis syndrome: single-center experience

• Published in: European journal of pediatrics 2023-12, Vol.182 (12), p.5473-5482
• Main Authors: Konte, Elif Kilic, Haslak, Fatih, Yildiz, Mehmet, Gucuyener, Neslihan, Ulkersoy, Ipek, Gunalp, Aybuke, Aslan, Esma, Adrovic, Amra, Sahin, Sezgin, Barut, Kenan, Kasapcopur, Ozgur
• Format: Article
• Language: English
• Subjects: Adenitis; Aphthous stomatitis; Arthralgia; Colchicine; Corticosteroids; Erysipelas; Exanthema; Familial Mediterranean fever; Family medical history; Fever; Inflammatory diseases; Medicine; Medicine & Public Health; Multivariate analysis; Mutation; Myalgia; Patients; Pediatrics; Pharyngitis; Point mutation; Pyrin protein; Rheumatology; Risk factors; Tonsillopharyngitis
• ISSN: 1432-1076; 0340-6199; 1432-1076
• DOI: 10.1007/s00431-023-05209-4

Despite the advanced knowledge concerning autoinflammatory diseases (AID), more data regarding the optimal treatment options and outcomes of the children who met the criteria of more than one AID are required. This study aimed to describe the demographic and clinical characteristics of children from familial Mediterranean fever (FMF)-endemic countries who meet both the FMF and the periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome criteria. Moreover, we aimed to measure the response rates to colchicine and tonsillectomy and evaluate the factors affecting the colchicine response in these patients. The study was conducted at pediatric rheumatology tertiary centre. A total of 131 patients (58 females; 73 males) who met both the modified Marshall and pediatric FMF criteria were included. The median age at onset was 18 months (1–77 months), and the mean age at diagnosis was 47 ± 21.88 months. The median interval between episodes was 21 (7–90) days. The median disease duration was 46 (6–128) months. Consanguineous marriage was detected in 17 (13%) of the patients. The most common clinical finding was fever (100%), followed by exudative pharyngitis (88.5%), abdominal pain (86.3%), arthralgia (61.8%), stomatitis (51.1%), adenitis (42%), myalgia (28.7%), chest pain (16%), maculopapular rash (12.2%), arthritis (8.4%), and erysipelas-like rash (4.6%). MEFV gene variants were identified in 106 (80.9%) patients. The most common variants were M694V heterozygous (29%). We found that patients with tonsillopharyngitis, aphthous stomatitis, and PFAPA family history were more likely to be colchicine-resistant and tonsillectomy responsive, while those with exon 10 MEFV gene mutations were more prone to have a favorable response to colchicine.      Conclusion : PFAPA syndrome patients with exon 10 MEFV gene mutation, showing typical FMF symptoms, should be treated with colchicine, even after tonsillectomy. In multivariate analysis, PFAPA family history and lack of exon 10 MEFV gene mutations were independent risk factors for colchicine resistance. Thus, tonsillectomy may be recommended as a possible treatment option for these patients. It has yet to be clarified when colchicine treatment will be discontinued in patients whose attacks ceased after tonsillectomy that was performed due to colchicine unresponsiveness. What is Known: • A certain number of patients with periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome conco